Iterative Therapeutics Inc.

Chicago, IL

UEI
C1CEHZJYKV95
CAGE
50MG3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2201 W Campbell Park Dr #311, Chicago, IL 60612, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Enhanced NK cell activation via FC receptor ligand - cytokine combinations R43CA210884 National Cancer Institute (NIH) $150,000
Rapid response vaccines for botulinum neurotoxins R43AI096683 National Institutes of Health $587,806
Novel HER2 targeting immunotherapeutics for breast cancer R43AI081465 National Institutes of Health $500,128

Quick answers

Is Iterative Therapeutics Inc. registered in SAM.gov?

Yes. Iterative Therapeutics Inc.'s SAM.gov registration is active through August 21, 2027.

What is Iterative Therapeutics Inc.'s most recent federal award?

Iterative Therapeutics Inc.'s most recent federal grant award is Enhanced NK cell activation via FC receptor ligand - cytokine combinations (R43CA210884), from National Cancer Institute (NIH), on September 13, 2017.

On GovTribe

See Iterative Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login